NCT03861156 - D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | Biotech Hunter

Enrollment

290

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

August 15, 2021

Study Completion Date

May 31, 2023

Conditions

Solid TumorNSCLCEGFR T790M

Interventions

DRUG

D-0316

Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.

Trial Locations (1)

200030

Shanghai Chest Hospital, Shanghai